GlycoVaxyn, a Switzerland-based developer of conjugated vaccines that target bacterial infections, has raised CHF 11.5 million ($9.3m) in Series A funding from seed backers Sofinnova Partners and Index Ventures. www.glaxovaxyn.com
Return to search
![]()
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.